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Summary:  54 
Background: Impaired contractility is a fundamental abnormality in heart failure with reduced 55 
ejection fraction (HFrEF). We evaluated the pharmacokinetics of chronic therapy with the 56 
cardiac myosin activator omecamtiv mecarbil as well as its effect on cardiac function and 57 
structure in such patients. 58 
Methods: In this randomised, parallel-group, double-blind study, 448 patients from 87 sites in 59 
13 countries with stable, symptomatic chronic heart failure and left ventricular ejection fraction 60 
d40% were randomly assigned (1:1:1) using an interactive web response system to oral 61 
omecamtiv mecarbil (25 mg twice daily; or 25 mg twice daily with pharmacokinetic-guided 62 
uptitration to 50 mg twice daily, PK-titration group) or placebo for 20 weeks. The primary 63 
endpoint was the maximal omecamtiv mecarbil plasma concentration (Cmax); secondary 64 
endpoints were changes from baseline in cardiac function and dimensions, heart rate and NT-65 
proBNP at week 20. (ClinicalTrials.gov, NCT01786512) 66 
Findings: In patients enrolled from March 17, 2014 through March 5, 2015, Cmax (mean ± SD) at 67 
12 weeks was 200±71 and 318±129 ng/mL in the 25 mg (n = 147) and PK-titration (n = 141) 68 
groups, respectively. Differences were seen in all secondary endpoints by 20 weeks in the 69 
PK-titration group (n = 149) compared to placebo (n = 149): systolic ejection time [least square 70 
mean difference (95% CI); +25 (18, 32) msec, p<0·0001], stroke volume [+3·6 (0·5, 6·7) mL, 71 
p=0·0217], left ventricular end-systolic and end-diastolic dimensions [-1·8 (-2·9, -0·6) mm, 72 
p=0·0027; -1·3 (-2·3, 0·3) mm, p=0·0128, respectively], heart rate [-3·0 (-5·1, -0·8) bpm, 73 
p=0·0070] and NT-proBNP [-970 (-1672, -268) pg/mL, p=0·0069). The maximum changes from 74 
baseline in plasma troponin-I concentrations were greater in patients assigned to omecamtiv 75 
mecarbil [PK-titration: 0·020 ng/mL, (0·005, 0·038); median (Q1, Q3), p<0·0001] than placebo 76 
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[0·010  ng/mL (0·000, 0·020)]. No important differences in adverse clinical events were 77 
observed.  78 
Interpretation: In patients with chronic HFrEF, pharmacokinetic-guided dosing of omecamtiv 79 
mecarbil achieved plasma concentrations associated with improvements in cardiac performance 80 
and ventricular dimensions. 81 
Funding: Amgen in collaboration with Cytokinetics.  82 
  83 
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Introduction 84 
For over a century scientists have sought treatments to increase cardiac contractility1,2 85 
assuming that improvement in ventricular systolic performance may blunt deleterious 86 
neurohormonal activation and reverse adverse ventricular remodelling leading to improved 87 
clinical outcomes. Currently available pharmacologic agents that increase cardiac contractility 88 
have concomitant vascular effects (e.g. dobutamine, milrinone, levosimendan, dopamine) and 89 
may provoke important adverse clinical effects such as tachycardia, hypotension, arrhythmias 90 
and myocardial ischaemia, which may increase morbidity and mortality and confound their 91 
utility in testing the above assumption.3 These adverse effects may be a consequence of their 92 
mechanisms of action (adrenergic activation or phosphodiesterase inhibition) which increase 93 
myocardial cytoplasmic calcium or activate second messenger signalling resulting in pleiotropic 94 
effects on cardiac and vascular tissue rather than due to a direct consequence of the restoration of 95 
contractility.  96 
Omecamtiv mecarbil is a novel selective cardiac myosin activator that, in pre-clinical 97 
studies, increased myocardial systolic function and systolic ejection time, but did not increase 98 
intracellular calcium or the rate of change in left ventricular pressure (dP/dt), nor have any direct 99 
effect on vascular tissue, cardiovascular receptors or ion channels.4,5 In clinical studies with an 100 
intravenous formulation, omecamtiv mecarbil increased systolic ejection time and stroke volume 101 
while decreasing ventricular dimensions starting at plasma concentrations from 100-200 102 
ng/mL.6-8 In early dose-finding studies, the dose-limiting effect was excessive prolongation of 103 
systole with a resultant decrease in coronary blood flow during diastole leading to 104 myocardial ischaemia, occurring in some patients with plasma concentrations above 105 1,200 ng/mL.6,7 At well tolerated doses, a small increase in troponin concentration has been 106 
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noted in the absence of other clinical evidence of myocardial ischaemia.8 The Chronic Oral 107 
Study of Myosin activation to Increase Contractility in Heart Failure (COSMIC-HF; 108 
ClinicalTrials.gov NCT01786512) was designed to test the hypothesis that administration of oral 109 
omecamtiv mecarbil for 20 weeks using a pharmacokinetic-guided dose titration strategy would 110 
result in effective and well-tolerated plasma concentrations that improve ventricular systolic 111 
function and favourably decrease ventricular dimensions.  112 
 113 
Methods 114 
Study design 115 
COSMIC-HF was an international, multicentre, randomised, parallel group, placebo-116 
controlled, double-blind study conducted at 87 sites in 13 countries (see Supplementary 117 
Appendix for listing of sites). Ethics committees approved the study at each centre. The study 118 
protocol (see Supplementary Appendix) is available with the full text of this article at 119 
thelancet.com.  120 
 121 
Patients 122 
All patients provided written informed consent. Eligible patients were aged 18 to 85 years with 123 
chronic heart failure (NYHA class II or III) treated with stable, optimal pharmacological therapy 124 
for at least 4 weeks, and had an N-terminal-B-type natriuretic peptide (NT-proBNP) of at least 125 
200 pg/mL (e1200 pg/mL if in atrial fibrillation at presentation) and left ventricular ejection 126 
fraction d40% with acceptable image quality as determined by central reading of the screening 127 
echocardiogram. Patients were excluded if they had recent acute myocardial infarction, unstable 128 
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angina, or persistent angina at rest, were receiving treatment with chronic antiarrhythmic therapy 129 
(except amiodarone), or had severe chronic kidney disease (estimated glomerular filtration rate 130 
< 30 mL/min/1·73 m2 at screening). Randomisation was stratified by presence of atrial 131 
fibrillation with the proportion of patients with atrial fibrillation limited to approximately 20% of 132 
study population. Complete eligibility criteria are listed in the Supplementary Appendix.  133 
 134 
Randomisation and Masking 135 
Eligible patients were randomised via an interactive web response system based on a computer-136 
generated schedule prepared by Amgen before the start of the study stratified by presence or 137 
absence of atrial fibrillation/ flutter in a 1:1:1 ratio to three treatment groups: two groups 138 
received oral omecamtiv mecarbil [fixed dose group: 25 mg twice daily; pharmacokinetic (PK)-139 
titration group: 25 mg twice daily uptitrated to 50 mg twice daily] or matching oral placebo. 140 
 141 
Procedures 142 
Patients entered a screening period for up to 30 days and had tests including a 12-lead 143 
electrocardiogram (ECG), blood samples, and echocardiogram and eligible patients were 144 
randomised to one of the three groups. In the PK-titration group, PK-guided dose titration was 145 
employed to minimise the possibility of omecamtiv mecarbil plasma concentrations 146 
>1,000 ng/mL. Patients in the PK-titration group received 25 mg twice daily for 2 weeks to reach 147 
steady-state and if the trough omecamtiv mecarbil plasma concentration (Cpredose) at 2 weeks was 148 
<200 ng/mL, then patients were uptitrated at week 8 to 50 mg twice daily, while those with 149 
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Cpredose e200 ng/mL continued on 25 mg twice daily. Study drug was administered for 20 weeks 150 
with a week 24 follow-up visit.  151 
Full details of the study procedures are in the Supplementary Appendix. Intensive 152 
pharmacokinetic sampling was performed at the end of week 2 and week 12 over a period of 8 153 
hours on each day. After week 8, visits were every 4 weeks until week 24. Transthoracic 154 
echocardiographic assessments were performed at screening, week 12 and week 20 (all centrally 155 
analysed, blinded to treatment assignment). Blood samples were obtained at specified visits for 156 
central analysis, including measurement of troponin I (cTnI; Siemens ADVIA Centaur Ultra 157 
Troponin I)9,10 at baseline, weeks 2, 8, 12, 16, 20 and 24. Investigator-reported events suspicious 158 
of myocardial ischaemia or increases in cTnI [if cTnI > 0·04 ng/mL (99%URL) when prior level 159 
was undetectable or if cTnI > 0·03 ng/mL (10% CoV) greater than any prior detectable value] 160 
triggered an evaluation of possible cardiac ischaemia or infarction by the Clinical Events 161 
Committee (CEC).  162 
 163 
Outcomes 164 
The primary endpoint was the maximal concentration of omecamtiv mecarbil (Cmax) during 165 
dosing at weeks 2 and 12 and the concentration prior to the morning dose (Cpredose) at weeks 2, 8, 166 
12, 16, and 20. Secondary endpoints were changes from baseline in systolic ejection time (SET), 167 
stroke volume, left ventricular end-systolic (LVESD) and end-diastolic (LVEDD) dimensions, 168 
heart rate and NT-proBNP at week 20. Additional pre-specified exploratory echocardiographic 169 
endpoints included left ventricular fractional shortening (LVFS), end-systolic (LVESV) and end-170 
diastolic (LVEDV) volumes, and ejection fraction (LVEF). The CEC adjudicated all 171 
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hospitalizations and deaths, as well as all investigator-reported and troponin-triggered potential 172 
episodes of myocardial ischaemia or infarction.  173 
 174 
Statistical analysis 175 
The primary endpoints of this study were the pharmacokinetic measures, Cmax and 176 
Cpredose, of omecamtiv mecarbil described above. Assuming the standard deviations (SDs) for 177 
Cmax and Cmin are in the range of 40 to 140 ng/mL,
6-8,11-13 142 subjects (assuming 5% subjects 178 
were excluded from the pharmacokinetic analysis set) would provide a 2-sided 95% confidence 179 
interval with half width of 6.6 to 23 ng/mL, which was considered sufficient for accurate 180 
population estimates of these concentrations. From prior work conducted in a similar patient 181 
population, “plasma concentrations of omecamtiv mecarbil as low as 100–200 ng/mL had some 182 
effect on cardiac function and the effect on stroke volume seems to plateau above 400 ng/mL. 183 
Plasma concentrations greater than 1200 ng/mL were not clinically tolerated in two of three 184 
patients who exceeded those levels.”7 Thus, we attempted to achieve Cmax greater than 200 185 
ng/mL and avoid exposures above 1000 ng/mL. In addition, with 150 subjects in each arm at 186 
two-sided alpha of 0·05, the statistical power for detecting a treatment effect on the 187 
echocardiographic endpoints of SET, stroke volume and LVESD was greater than 90% (see 188 
Supplementary Appendix, Protocol, Section 10.2). Treatment group differences for changes in 189 
echocardiographic variables, heart rate as measured by electrocardiogram, and NT-proBNP were 190 
estimated using a repeated measures model fitted separately for each variable and included the 191 
stratification factor of presence or absence of atrial fibrillation/flutter at randomisation, baseline 192 
value, treatment group, visit, and the treatment group by visit interaction. An unstructured 193 
covariance matrix was used to account for the correlation between visits within a subject. Least 194 
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squares mean differences with 95% confidence intervals (95%CI) of the mean relative to placebo 195 
are presented unless otherwise indicated. As the study was hypothesis generating, all p-values 196 
are nominal with no multiplicity adjustment.  197 
 198 
Role of funding source 199 
The study was funded by Amgen Inc. in collaboration with Cytokinetics. The Executive 200 
Committee designed and oversaw the conduct of the study and data analysis in collaboration 201 
with Amgen and Cytokinetics. Data were collected, managed, and analysed by the sponsor 202 
according to a predefined statistical analysis plan (see Supplementary Appendix). An external 203 
independent Data Monitoring Committee evaluated patient safety throughout the trial. The first 204 
author, who had unrestricted access to the data, prepared the first draft of the manuscript that was 205 
critically reviewed by all authors, who attested to the accuracy and completeness of the analyses 206 
and approved the final version of the manuscript for submission. 207 
 208 
Results  209 
Study patients 210 
Of 758 patients screened from March 17, 2014 through March 5, 2015 at 87 centres in 13 211 
countries, 448 were randomly assigned to either omecamtiv mecarbil fixed dose (n = 150; 25 mg 212 
twice daily), omecamtiv mecarbil PK-titration dose (n = 149) or placebo (n = 149; see Figure 1). 213 
The groups were balanced with respect to most baseline characteristics and patients were 214 
receiving recommended pharmacologic therapy for chronic heart failure (Table 1). More than 215 
60% had an ICD, CRT-P or CRT-D.  216 
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 217 
Pharmacokinetics  218 
At week 12, the Cpredose (mean ± SD) of omecamtiv mecarbil was 165±68 and 263±116 ng/mL 219 
and the mean Cmax was 200±71 and 318±129 ng/mL in the fixed dose and PK-titration groups, 220 
respectively (see Table 2). At week 8, 78 of 146 patients in the PK-titration group were up-221 
titrated to 50 mg bid. At Week 12 in patients with measurements available, 63 of 137 (46%) 222 
patients in the fixed dose and 110 of 127 (87%) patients in the PK-titration groups had Cmax 223 
greater than or equal to 200 ng/mL. All patients had a Cmax <1000 ng/mL and only one patient in 224 
the PK-titration group had a Cmax greater than 750 ng/mL. The maximal observed plasma 225 
concentration was 453 ng/mL and 831 ng/mL in the fixed dose and PK-titration groups, 226 
respectively.  227 
 228 
Outcomes 229 
All pre-specified secondary efficacy endpoints were significantly different from placebo in the 230 
omecamtiv mecarbil PK-titration group at week 20 (Figure 2). There were placebo-corrected 231 
increases in systolic ejection time of 11 (95%CI; 5, 18) msec (p=0·0007) in the fixed omecamtiv 232 
mecarbil 25 mg bid dose group and 25 (18, 32) msec (p<0·0001) in the PK-titration group at 233 
week 20. Additionally, there were placebo-corrected increases from baseline in stroke volume in 234 
the fixed dose and PK-titration groups [5 (2, 8) mL, p=0·0036; 4 (1, 7) mL, p=0·0217, 235 
respectively]. Left ventricular end-systolic and end-diastolic dimensions, as well as heart rate 236 
were reduced by omecamtiv mecarbil compared to placebo at week 20 only in the PK-titration 237 
group. Reductions in the plasma concentrations of NT-proBNP at 20 weeks were observed both 238 
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in patients assigned to the fixed dose [-822 (-1516, -127) pg/mL; p=0·0205] and PK-titration 239 
[-970 (-1672, -268) pg/mL, p=0·0069] groups.  240 
In pre-specified exploratory analyses, placebo-corrected reductions in NT-proBNP persisted four 241 
weeks after stopping omecamtiv mecarbil [fixed: -1327 (-2056, -597) pg/mL, p=0·0004; 242 
PK-titration: -1306 (-2046, -566) pg/mL, p=0·0006]. Additionally, in the PK-titration group, 243 
there were reductions in left ventricular end-diastolic and end-systolic volumes, as well as 244 
increases in fractional shortening at week 20 compared to placebo (Supplementary Appendix, 245 
Table).  246 
 247 
Safety  248 
Similar percentages of patients in the three groups completed study drug administration 249 
(Table 3). Adverse events, serious adverse events, and deaths were similar across randomised 250 
groups. Approximately one-quarter of the patients in the study had cardiac troponin I (cTnI) 251 
plasma concentrations above the 99th percentile upper reference limit (0·04 ng/mL) at baseline 252 
with no difference between the groups. At week 20, increased concentrations of cTnI compared 253 
to placebo were noted in patients receiving omecamtiv mecarbil; median change from baseline 254 
was 0·001 and 0·006 ng/mL in the fixed and PK-titration dose groups, respectively whereas 255 
there was no median change in the placebo group (Table 3). An analysis of the maximum change 256 
from baseline troponin at any time during the 20 weeks of treatment demonstrated that there was 257 
a significant increase in troponin in both the 25 mg bid (p=0·0029) and PK-titration (p<0·0001) 258 
groups compared to placebo. Over 92% of these increases were <0·1 ng/mL and 97% were 259 
<0·2 ng/mL in patients assigned to omecamtiv mecarbil as compared to 95% and 97% in patients 260 
assigned to placebo, respectively. Plasma concentrations of cTnI returned to baseline levels 261 
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within 4 weeks of discontinuing omecamtiv mecarbil. A patient’s maximum concentration of 262 
omecamtiv mecarbil was poorly predictive of their maximum change from baseline in troponin 263 
(Figure 3; r2=0·017). There were 278 potential events triggered by an increase in troponin that 264 
were submitted to the CEC for adjudication. Of these, none were adjudicated as an episode of 265 
myocardial ischaemia or a myocardial infarction.  266 
 267 
Discussion  268 
In COSMIC-HF, oral administration of omecamtiv mecarbil to patients with chronic heart failure 269 
with reduced ejection fraction achieved target plasma concentrations; almost twice as many 270 
patients in the pharmacokinetic (PK)-guided titration group attained target concentrations than in 271 
the fixed dose group. Patients in the PK-titration group had increased duration of ventricular 272 
systole and stroke volume, reduced ventricular dimensions and volumes and decreased NT-273 
proBNP and heart rate. These effects on cardiac function were similar to those seen in earlier 274 
preclinical 4,5 and clinical studies 6-8 using short-term intravenous omecamtiv mecarbil. Unlike 275 
currently available inotropes and inodilators, no increases in clinical episodes of tachycardia, 276 
hypotension, atrial or ventricular arrhythmia, cardiac ischaemia, or myocardial infarction were 277 
observed. The incidence of clinical adverse events was similar with placebo and omecamtiv 278 
mecarbil though limited by small sample size, and patients receiving omecamtiv mecarbil had 279 
small increases in plasma concentrations of troponin that returned to baseline after omecamtiv 280 
mecarbil was discontinued. These findings from COSMIC-HF support the hypothesis that direct 281 
and selective augmentation of systolic function can reduce myocardial wall stress (as suggested 282 
by the decrease in NT proBNP) and possibly sympathetic activation (as suggested by the 283 
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decrease in heart rate), and promote favourable ventricular remodelling in patients with chronic 284 
heart failure with reduced ejection fraction.  285 
Omecamtiv mecarbil is a selective cardiac myosin activator that binds to the motor 286 
domain of myosin and increases its probability of engaging the actin filament productively to 287 
produce force during systole.4 This mechanism of action directly improves cardiac contractility 288 
by specifically modulating the function of the sarcomere. In preclinical studies, omecamtiv 289 
mecarbil did not increase the calcium transient in cardiac myocytes, and has no known activity 290 
other than its action on cardiac myosin that could account for its effects on cardiovascular 291 
function. In animals4,5 and humans,6-8 the pharmacodynamic signature of omecamtiv mecarbil is 292 
an increase in the systolic ejection time. This finding is a reflection of the mechanism of action 293 
of omecamtiv mecarbil; the increase in the number of myosin heads interacting with actin 294 
filaments facilitates a longer duration of systole, even as cytoplasmic calcium concentrations fall 295 
in the myocyte.  296 
Since the 1960s, it has been recognized that systolic ejection times are shortened by 10-297 
70 msec in patients with systolic heart failure compared to healthy controls.14 The exact 298 
mechanism of this decreased systolic ejection time is unknown although it is proportional to the 299 
decrease in stroke volume. In a recent analysis of 2,077 patients from the ARIC study, decreased 300 
systolic ejection time was directly related to decreased fractional shortening and predicted the 301 
future risk of heart failure.15 Consistent with studies of intravenous administration in healthy 302 
volunteers and patients with acute and chronic heart failure,6-8 in this study of chronic oral 303 
administration of omecamtiv mecarbil, systolic ejection times were increased on average from 304 
11-25 msec, effectively extending the systolic ejection time toward normal.  305 
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In a contemporary model of the pathogenesis of heart failure, decreased systolic function 306 
leads to multiple pathophysiological adaptations, including activation of the renin-angiotensin-307 
aldosterone (RAAS) and sympathetic systems and adverse ventricular remodelling resulting in 308 
deteriorating cardiac function and worsening symptoms. This hypothesis has been supported by 309 
multiple trials demonstrating the ability of RAAS and sympathetic blockade (e.g. ACE 310 
inhibitors, ARBs, MRAs, and beta blockers) or augmentation of vasodilating peptides (e.g. 311 
neprilysin inhibitors) to slow or prevent the progression of heart failure. However, to date, no 312 
pharmacological therapy has been available to test the hypothesis that directly and selectively 313 
augmenting cardiac function can also delay progression of heart failure. While this study was not 314 
designed to specifically test this hypothesis, 20 weeks of omecamtiv mecarbil administration 315 
reduced left ventricular end-diastolic dimensions and volumes consistent with favourable cardiac 316 
remodelling. Although ventricular dimensions were not reassessed after discontinuation of 317 
omecamtiv mecarbil, the persistent decrease in NT-proBNP suggests that the effects on cardiac 318 
dimensions do not merely reflect a direct short-term effect on systolic function. The decreased 319 
heart rate observed in patients assigned to omecamtiv mecarbil in this study, as well as earlier 320 
preclinical 4,5 and clinical studies,6-8 is also consistent with reduced sympathetic activation. These 321 
findings from COSMIC-HF may support the hypothesis that directly improving systolic function 322 
can reverse maladaptive structural changes associated with progression of heart failure. 323 
In several prior studies, therapies that improve ventricular remodelling have also had 324 
beneficial effects on clinical outcomes. In a meta-analysis of the relationship between drug- or 325 
device-related changes in ventricular volumes and subsequent mortality,16 therapies that 326 
decreased end-diastolic or end-systolic volumes by 11 mL were associated with a 65-75% 327 
likelihood of the therapy having a favourable effect on mortality. In the MADIT-CRT trial, a 5% 328 
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reduction in ventricular volumes was associated with an approximately 14-20% decrease in the 329 
combined endpoint of death or heart failure hospitalizations.17 Plasma concentrations of 330 
natriuretic peptides have also been a strong predictor of adverse clinical outcomes, including 331 
cardiovascular death, 18,19 and in some studies are stronger predictors of clinical outcomes than 332 
left ventricular ejection fraction or volumes.20 Similar changes in these measures were 333 observed in COSMIC-HF following treatment with omecamtiv mecarbil warranting further 334 investigation of its effects on cardiovascular outcomes.  335 
COSMIC-HF was a pharmacokinetic study that compared two dosing strategies with a 336 
goal of achieving effective and well-tolerated plasma concentrations. The PK-titration group was 337 
able to achieve the target plasma concentration of >200 ng/mL in 87% of the patients, compared 338 
to 46% in the fixed dose group, and importantly, no patients in either group had plasma 339 
concentrations above 1,000 ng/mL. However, a small, though potentially concerning increase in 340 
plasma troponin concentration was noted temporally associated with administration of 341 
omecamtiv mecarbil, but not correlated with maximal omecamtiv mecarbil plasma 342 
concentrations, similar to findings in a previous study of patients with acute heart failure.8 The 343 
magnitude of this troponin release is similar to the range of those experienced by healthy 344 
endurance athletes21 and are within the limits of diurnal variation for patients without heart 345 
failure.22 None of the increases in troponin were adjudicated as myocardial ischaemia in the 346 
current trial and occurred in the context of improving systolic function, decreasing ventricular 347 
volumes and declining NT-proBNP. Whether these troponin elevations are related to myocardial 348 
damage or other mechanisms (e.g. exosomal trafficking23) is unknown and its impact on clinical 349 
events can only be addressed by a large outcomes trial.  350 
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COSMIC-HF was designed as a Phase 2, pharmacokinetic study without formal 351 
hypothesis-testing, and consequently, the echocardiographic findings should be considered 352 
hypothesis-generating. While the study was prospectively powered for the secondary efficacy 353 
endpoints of SET, stroke volume and LVESD and all pre-specified secondary efficacy endpoints 354 
were significantly different than placebo in the PK-titration group, there were no adjustments for 355 
multiple comparisons. With these caveats, the results of COSMIC-HF support the hypothesis that 356 
directly and specifically improving cardiac systolic function with a cardiac myosin activator 357 
results in favourable ventricular remodelling. However, its effects on long-term morbidity and 358 
mortality remain untested and the risks and benefits of omecamtiv mecarbil can only be 359 
determined by a large outcomes trial.   360 
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Research in context  361 
Evidence before this study 362 
This study incorporated three major lines of evidence in its inception and design. The 363 
first line of evidence was that a central defect in heart failure with reduced ejection fraction 364 
(HFrEF) is a decrease in systolic function. The question emerges as to whether selectively 365 
improving systolic function can reverse some of the other pathophysiologic processes in HFrEF 366 
and result in improved clinical outcomes. The second line of evidence emerged from a review of 367 
the literature of clinical studies of oral positive inotropes in patients with heart failure [PubMed, 368 
see Supplementary Appendix]. Review of this literature revealed many agents given to improve 369 
systolic function whose mechanism of action directly or indirectly increased intracellular 370 
calcium and that acted on both the myocardium and vasculature. The poor clinical outcomes of 371 
oral agents that did eventually advance to Phase III trials, such as milrinone, vesnarinone, 372 
enoximone, and flosequinan, were also evident. In addition, this review established that, to-date, 373 
the hypothesis of whether a pharmacologic agent that worked solely upon cardiac contractility 374 
could favourably influence ventricular remodelling had not been tested. The third line of 375 
evidence is derived from the studies performed with omecamtiv mecarbil to date,6-8,11-13 which 376 
demonstrated that plasma concentrations of 100-200 ng/mL and above of intravenous omecamtiv 377 
mecarbil could acutely improve cardiac function and dimensions and provided information on 378 
the pharmacokinetics and pharmacodynamics of intravenous omecamtiv mecarbil, as well as 379 
preliminary data on the pharmacokinetics of oral formulations. These data provided the 380 
foundation for selecting the target plasma concentration ranges used in COSMIC-HF, as well as 381 
for the hypothesis that oral omecamtiv mecarbil could chronically improve cardiac performance 382 
and perhaps favourably influence ventricular remodelling.  383 
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Added value of this study 384 
COSMIC-HF demonstrated that using a PK-titration strategy, the great majority of 385 
patients achieved the targeted omecamtiv mecarbil plasma concentrations, avoiding excessive 386 
drug concentrations where prior adverse effects had been noted. However, an increase in 387 
circulating troponins was also noted which were poorly related to maximum plasma omecamtiv 388 
mecarbil concentrations. This study provided evidence that omecamtiv mecarbil may improve 389 
cardiac function associated with favourable reverse ventricular remodelling and reduced NT-390 
proBNP.  391 
Implications of all the available evidence 392 
The results of COSMIC-HF support advancing omecamtiv mecarbil into a Phase III trial 393 
by providing essential data on the dosing strategy and supporting the hypothesis that selectively 394 
increasing cardiac function can result in improved ventricular remodelling. The extension of this 395 
hypothesis, that this improvement in ventricular function can also result in improved clinical 396 
outcomes, needs to be tested in a prospectively powered outcomes trial.   397 
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Figure legends: 512 
Figure 1: Trial profile 513 
 514 
Figure 2: Efficacy Endpoints 515 
The least squares mean ± SEM change from baseline at week 20 are shown by treatment group 516 
of the systolic ejection time (Panel A), stroke volume (Panel B), left ventricular end-systolic 517 
(Panel C) and end-diastolic (Panel D) dimensions, heart rate (Panel E), and NT-proBNP (Panel F). 518 
The 25 mg group received 25 mg bid for 20 weeks, while the PK-titration group received 25 mg 519 
twice daily for 2 weeks to reach steady-state and if the trough omecamtiv mecarbil plasma 520 
concentration (Cpredose) was < 200 ng/mL, then patients were uptitrated at week 8 to 50 mg 521 
twice daily, while those with Cpredose ≥ 200 ng/mL continued on 25 mg twice daily. 522 
Approximately 60% of patients were up-titrated to 50 mg twice daily. P-values represent 523 
comparisons to placebo group using a repeated measures model. The model was fitted 524 
separately for each variable and included the stratification factor of presence or absence of 525 
atrial fibrillation/flutter at randomisation, baseline value, treatment group, visit, and the 526 
treatment group by visit interaction.  527 
 528 
Figure 3: Maximum Change from Baseline in Troponin (μg/mL) by Omecamtiv Mecarbil 529 
Maximum Concentration (ng/mL)  530 
Shown are the maximal change from baseline in troponin and the maximum omecamtiv 531 
mecarbil plasma concentration plotted individually for each patient (n = 429). The linear 532 
regression (solid line) demonstrates a very poor correlation of the maximum omecamtiv 533 
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mecarbil plasma concentration (Max OM) with the maximal change from baseline in troponin 534 
(Max Troponin) with r2 = 0·017.   535 
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Tables 536 
Table 1: Baseline Characteristics of Patients, According to Treatment Group  537 
 Placebo 
 (n = 149) 
Omecamtiv 
Mecarbil  
25 mg BID            
 (n = 150) 
Omecamtiv 
Mecarbil  
Titration Group 
(n = 149) 
Age — years  64±10 63 ±10 63 ±12 
Men — no. (%) 119 (80) 127 (85) 125 (84) 
White Race — no. (%) 136 (91) 142 (95) 140 (94) 
Body Mass Index — kg/m2  29·7±5·7 28·5±5·6 29·5±6·1 
Systolic blood pressure — mmHg  119±14 121±16 119±16 
Heart rate — bpm  69±10 67±11 70±12 
HF characteristics 
   
Ischemic heart disease — no. (%) 89 (60) 97 (65) 101 (68) 
Years from HF Diagnosis 8·0±7·1 7·7±7·9 7·7±6·5 
Hospitalised for HF in past 12 
months— no. (%) 
38 (26) 51 (34) 38 (26) 
NYHA class II/III — no. (%) 105 (70)/  44 (30) 
102 (68)/  
48 (32) 
107 (72)/  
42 (28) 
Co-morbidities    
Angina — no. (%) 32 (21) 41 (27) 50 (34) 
History of:     
Myocardial Infarction — no. (%) 82 (55) 83 (55) 82 (55) 
Unstable angina — no. (%) 20 (13) 28 (19) 27 (18) 
Coronary angiogram with 
clinically significant stenosis — 
no. (%) 
70 (47) 73 (49) 78 (52) 
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 Placebo 
 (n = 149) 
Omecamtiv 
Mecarbil  
25 mg BID            
 (n = 150) 
Omecamtiv 
Mecarbil  
Titration Group 
(n = 149) 
Percutaneous Intervention — no. 
(%) 
62 (42) 61 (41) 63 (42) 
CABG — no. (%) * 28 (19) 47 (31) 40 (27) 
Persistent A Fib/Flutter — no. (%)  33 (22) 28 (19) 24 (16) 
Diabetes mellitus — no. (%)  61 (41) 70 (47) 55 (37) 
Hypertension — no. (%) 101 (68) 94 (63) 109 (73) 
Dyslipidaemia — no. (%) 111 (74) 95 (63) 99 (66) 
Transient ischemic attack — no. (%) 9 (6) 10 (7) 5 (3) 
Stroke — no. (%) 14 (9) 15 (10) 14 (9) 
Chronic obstructive pulmonary 
disease — no. (%) 
23 (15) 21 (14) 15 (10) 
Laboratory variables a    
Troponin I — ng/mL,  
median (Q1, Q3) 
0·025  
(0·016, 0·041) 
0·022  
(0·016, 0·039) 
0·022  
(0·016, 0·042) 
NT-proBNP — pg/mL,  
median (Q1, Q3) 
1719  
(699, 3242) 
1538  
(634, 3427) 
1719  
(881, 3060) 
eGFR — mL/min/1·73m2  65±19 63±19 65±19 
Heart Failure Therapies – no. (%)    
ACE inhibitor and/or ARB 140 (94) 142 (95) 137 (92) 
ACE inhibitors  106 (71) 104 (69) 97 (65) 
ARBs 36 (24) 42 (28) 40 (27) 
Beta-blockers 146 (98) 146 (97) 144 (97) 
MRAs 88 (59) 87 (58) 94 (63) 
Diuretics other than MRAs 125 (84) 128 (85) 134 (90) 
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 Placebo 
 (n = 149) 
Omecamtiv 
Mecarbil  
25 mg BID            
 (n = 150) 
Omecamtiv 
Mecarbil  
Titration Group 
(n = 149) 
Digitalis glycosides 31 (21)  24 (16) 32 (22) 
Implantable cardiac defibrillator 
(ICD) only 
52 (35) 58 (39) 60 (40) 
Cardiac resynchronisation therapy 
(CRT) without ICD 
6 (4) 2 (1) 1 (1) 
Cardiac resynchronisation therapy 
(CRT) with ICD 
30 (20) 39 (26) 37 (25) 
Echocardiographic Variables    
SET — msec 299±37 305±39 298±33 
Stroke volume — mL 52·2±14·9 54·1±15·4 52·4±14·9 
LVESD — mm 53·1±9·6 52·4±8·6 53·9±9·1 
LVEDD — mm 61·9±9·6 61·2±8·3 62·8±9·0 
Fractional Shortening — % 18·9±5·5 18·7±5·5 18·4±5·3 
LVESV — mL 155·9±89·0 144·2±61·3 157·1±77·7 
LVEDV — mL 215·7±99·2 199·9±69·1 215·9±88·8 
Ejection Fraction — % 29·3±7·4 29·3±7·5 29·0±7·3 
    
 538 
Note: Mean ± SD, unless otherwise noted. a Laboratory variables, heart failure therapies and 539 
echocardiographic variables excludes 3 patients who were randomised but not dosed. SET = 540 
systolic ejection time, LVESD/ LVEDD = left ventricular end-systolic/ end-diastolic dimension, 541 
LVESV/ LVEDV = left ventricular end-systolic/ end-diastolic volume. * p <0·05, all others 542 
p > 0·05; P-values provided as a measure of baseline difference and not for statistical testing. 543 
Continuous variable p-values are from ANOVA tests and categorical variable p-values from chi-544 
square tests.  545 
  546 
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Table 2: Pharmacokinetic Primary variables:  547 
 548 
Values are presented as Mean±SD (CV%); Cpredose = plasma concentration prior to an OM 549 
dose; Cmax = maximum observed plasma concentration. 550 
*Included 5 subjects who discontinued the study early prior to day 50 and were not treated 551 
after week 8; Patients in the PK-titration group received 25 mg twice daily for 2 weeks to 552 
reach steady-state and if the trough omecamtiv mecarbil plasma concentration (Cpredose) was 553 
<200 ng/mL, then patients were uptitrated at week 8 to 50 mg twice daily, while those with 554 
Cpredose ≥200 ng/mL continued on 25 mg twice daily.  555 
  556 
  
Omecamtiv mecarbil 
25 mg 
Omecamtiv mecarbil 
PK-Titration Group* 
  
(N =147) (N =141) 
Cpredose (ng/mL) 
 
Week 2 174±62.2 (35.7) 179±68.8 (38.4) 
 
Week 8 156±69.1 (44.2) 161±74.4 (46.1) 
 
Week 12 165±67.9 (41.3) 263±116 (44.1) 
 
Week 16 155±69.0 (44.6) 240±120 (50.0) 
 
Week 20 149±71.2 (47.8) 239±118 (49.5) 
Cmax (ng/mL) 
 
Week 2 212±70.4 (33.2) 212±81.0 (38.2) 
 
Week 12 200±71.1 (35.6) 318±129 (40.5) 
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Table 3: Safety Variables and Adverse Events 557 
No. (%) 
Placebo 
 (n = 149) 
Omecamtiv 
Mecarbil  
25 mg BID            
 (n = 150) 
Omecamtiv 
Mecarbil  
Titration Group 
(n = 146) a 
Tolerability     
Completed IP  133 (89) 134 (89) 127 (85) 
Discontinued IP  16 (11) 16 (11) 19 (13) 
Troponin I — ng/mL    
Change to Week 20, median 
(Q1,Q3) 
0·000 
(-0·007, 0·004) 
0·001 
(0·000, 0·012) 
0·006 
(0·000, 0·024) 
Maximum change from 
baseline, median (Q1, Q3) 
0·010 
(0·000, 0·020) 
0·016 
(0·003, 0·034) 
0·020 
0·005, 0·038) 
Change to Week 24, median 
(Q1,Q3) 
0·000 
(-0·006, 0·008) 
0·000 
(-0·002, 0·009) 
0·000 
(-0·003, 0·010) 
 
Adjudicated Clinical Events     
Hospitalisation 24 (16) 24 (16) 26 (18) 
Heart failure 11 (7) 9 (6) 10 (7) 
MI 1 (1) - 1 (1) 
Unstable angina - 1 (1) - 
Chest pain (non-MI/UA) 1 (1) 2 (1) 2 (1) 
Other categories 15 (10) 14 (9) 15 (10) 
Total MI c 2 (1) - 1 (1) 
Death 4 (3) 1 (1) 3 (2) 
     CV Death 2 (1) 1 (1) 2 (1) 
Any Adverse Event  91 (61) 92 (61) 95 (65) 
Most-common Adverse Event b    
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No. (%) 
Placebo 
 (n = 149) 
Omecamtiv 
Mecarbil  
25 mg BID            
 (n = 150) 
Omecamtiv 
Mecarbil  
Titration Group 
(n = 146) a 
Dyspnoea 8 (5) 11 (7) 13 (9) 
Fatigue 4 (3) 14 (9) 9 (6) 
Dizziness 6 (4) 8 (5) 10 (7) 
Cardiac failure 13 (9) 5 (3) 8 (5) 
Nasopharyngitis 5 (3) 8 (5) 5 (3) 
AE Leading to study 
discontinuation 
12 (8) 8 (5) 12 (8) 
Serious Adverse Events  30 (20) 36 (24) 32 (22) 
Cardiac SAEs 19 (13) 18 (12) 17 (12) 
Cardiac failure 4 (3) 3 (2) 5 (3) 
Cardiac failure acute 1 (1) 3 (2) 3 (2) 
Cardiac failure congestive 3 (2) 3 (2) 3 (2) 
Angina pectoris - 3 (2) 1 (1) 
Ventricular tachycardia 1 (1) 2 (1) 1 (1) 
 558 
a Tolerability includes 3 additional patients who were randomised but not dosed; b Treatment 559 
Emergent Adverse Events occurring in ≥5% of patients; c Includes 0/278 increased troponin-560 
triggered potential myocardial ischaemia/ infarction events adjudicated by CEC as MI; AE = 561 
adverse event; CV = cardiovascular; IP = Investigational product; MI = myocardial infarction; SAE 562 
= serious adverse event; UA = unstable angina.  563 
 564 
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Figure 1: Trial Profile 
 
 
  
758 screened 
448 randomised 
310 not enrolled 
   280 did not meet inclusion criteria 
   30 met criteria but did not enroll 
149 Placebo 
  
150 Fixed-dose omecamtiv 
mecarbil (25 mg bid)  
149 randomised         
   149 received study drug 
150 randomised         
   150 received study drug 
4 discontinued  
   4 death 
5 discontinued  
   3 withdrawal of consent 
   1 lost to follow-up 
   1 death    
145 completed the study 145 completed the study 
149 Titration omecamtiv 
mecarbil (25  50 mg bid*) 
149 randomised  
   146 received study drug 
12 discontinued  
   7 withdrawal of consent 
   2 decision by sponsor  
   3 death    
137 completed the study 
448 enrolled in the  
Expansion  Phase 
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Figure 2: Efficacy Endpoints 
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Figure 2: Efficacy Endpoints (continued) 
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Figure 3: Maximum Change from Baseline in Troponin (μg/mL) by Maximum Concentration of Omecamtiv Mecarbil (ng/mL)  
  
